Epidemiologic profile of type-specific human papillomavirus infection after initiation of HPV vaccination

Masayuki Sekine*, Manako Yamaguchi, Risa Kudo, Sharon J.B. Hanley, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi, Takayuki Enomoto

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
3 Downloads (Pure)


Organized human papillomavirus vaccination (OHPV) in Japan was introduced in 2010 for girls aged 12–16 years who were born in 1994 or later. The rate of OHPV coverage was 70–80%. However, after suspension of the government vaccination recommendation, the coverage dramatically decreased. We aim to investigate the change in prevalence of HPV infection after the initiation of HPV vaccination. We recruited females aged 20–21 years attending public cervical cancer screening from 2014 to 2017 fiscal years (April 2014 to March 2018). Residual Pap test specimens were collected for HPV testing. We compared the prevalence of HPV type-specific infection between women registered in 2014 (born in 1993–1994, including the pre-OHPV generation) and registered in 2015–2017 (born in 1994–1997, the OHPV generation). We collected 2379 specimens. The vaccination coverage figures were 30.7%, 86.6%, 88.4% and 93.7% (p < 0.01) from 2014 to 2017, respectively. The prevalence of HPV16/18 infection significantly decreased from 1.3% in 2014 to 0% in 2017 (p = 0.02). The three most prevalent types were HPV52, 16 and 56 in 2014, and HPV52, 58 and 56 in 2015–2017, respectively. HPV16 and 33 infection rates decreased. On the other hand, the HPV58 infection rate was obviously increased after OHPV from 0.3% to 2.1%. Our study demonstrates that the prevalence of HPV16/18 infection dramatically decreased and the profile of type-specific HPV infection was changed after OHPV.

Original languageEnglish
Article number425
Pages (from-to)1-8
Number of pages8
Issue number3
Early online date29 Jul 2020
Publication statusPublished - 1 Sept 2020

Bibliographical note

Funding Information:
This work was supported by the Health and Labor Sciences Research Grant [26272001] and the Japanese Agency for Medical Research and Development [JP15ck0106103].
Acknowledgments: We would like to thank Yuka Watanabe, Sachiko Ono, Anna Ishida, Yoko Motoki and the administrator of Niigata city for their support in conducting the survey


  • Cross-protection
  • HPV infection
  • HPV vaccine
  • Type replacement


Dive into the research topics of 'Epidemiologic profile of type-specific human papillomavirus infection after initiation of HPV vaccination'. Together they form a unique fingerprint.

Cite this